

S2 Table. Differentially expressed genes correlated in prognostic of triple-negative breast cancer

No.	Gene	NT vs. T p-value ^{a)}	NT vs. T Fold Change	Event vs. non- event p-value ^{a)}	Event vs. non-event Fold change	Cox p-value
1	<i>ANKRD36</i>	1.74E-03	1.84	3.25E-02	1.83	2.96E-03
2	<i>ANKRD36BP2</i>	6.21E-11	18.48	3.48E-02	2.02	9.16E-04
3	<i>BSPRY</i>	1.40E-11	17.68	1.07E-02	2.11	9.57E-04
4	<i>C12orf65</i>	3.02E-12	4.32	5.00E-05	-1.67	2.37E-03
5	<i>C1orf198</i>	3.22E-12	7.13	2.93E-02	1.55	2.17E-04
6	<i>CCDC114</i>	8.71E-03	1.91	1.21E-02	2.06	2.36E-04
7	<i>CLDN4</i>	4.35E-10	6.70	3.94E-03	1.89	1.48E-02
8	<i>CUEDC1</i>	2.42E-07	2.79	1.25E-02	1.63	1.60E-02
9	<i>DCLK2</i>	3.36E-05	2.12	1.30E-02	1.78	4.08E-04
10	<i>DGKH</i>	1.32E-10	8.43	5.93E-04	2.00	2.12E-04
11	<i>DIP2B</i>	2.84E-12	6.36	5.11E-03	1.69	3.34E-03
12	<i>DISC1</i>	2.73E-04	2.16	2.37E-02	1.57	2.47E-02
13	<i>EMP1</i>	6.35E-08	3.00	1.30E-02	1.89	1.88E-04
14	<i>GADD45B</i>	4.63E-11	6.12	1.46E-02	1.59	6.62E-03
15	<i>GLS</i>	2.84E-12	17.00	3.77E-03	1.57	1.44E-02
16	<i>GYPC</i>	1.83E-07	2.91	3.25E-02	-1.56	3.82E-02
17	<i>H2AFX</i>	2.84E-12	34.69	9.89E-03	-1.58	4.62E-02
18	<i>HRAS</i>	9.15E-04	1.65	7.76E-03	-1.66	2.49E-02
19	<i>KLF6</i>	1.04E-02	-1.25	4.26E-02	1.82	2.41E-02
20	<i>KLF7</i>	2.20E-02	-1.42	2.05E-02	1.72	2.28E-04
21	<i>LYST</i>	2.48E-10	3.41	2.28E-02	1.81	1.00E-04
22	<i>MALAT1</i>	3.48E-10	-3.29	2.64E-02	1.80	1.94E-03
23	<i>MCM3AP.AS1</i>	6.58E-11	6.76	1.30E-02	1.64	1.34E-03
24	<i>MICALL2</i>	2.47E-05	2.18	2.64E-02	-1.64	2.39E-02
25	<i>MT2A</i>	3.22E-12	30.27	5.11E-03	1.78	4.21E-04
26	<i>NBPF20</i>	3.22E-12	-6.01	3.60E-02	1.51	4.17E-03
27	<i>NOTCH2</i>	9.75E-12	4.35	1.83E-02	1.95	1.17E-04
28	<i>NOXA1</i>	6.87E-06	3.14	3.48E-02	2.00	9.83E-05
29	<i>NPR3</i>	3.39E-03	4.12	1.70E-02	4.13	5.60E-05
30	<i>NR6A1</i>	6.43E-10	4.62	3.25E-02	1.69	1.29E-02
31	<i>PAK3</i>	1.78E-02	2.41	2.93E-02	-2.36	4.49E-02
32	<i>PARD6B</i>	5.20E-11	7.99	2.28E-02	1.66	1.61E-03
33	<i>PEX1</i>	2.84E-12	9.00	2.30E-03	1.73	4.07E-02
34	<i>PRICKLE1</i>	7.84E-11	6.87	5.80E-03	1.53	2.55E-02
35	<i>PYCARD</i>	2.84E-12	13.06	3.30E-03	-1.79	2.85E-02
36	<i>RASA1</i>	3.42E-12	4.80	4.40E-02	1.81	6.45E-04
37	<i>RASD2</i>	4.39E-12	24.12	2.45E-02	2.16	5.51E-03
38	<i>RASGRP1</i>	2.84E-12	43.46	1.83E-02	2.22	8.07E-05
39	<i>RHPN2</i>	2.27E-11	13.39	2.00E-03	1.87	2.92E-02
40	<i>ROBO1</i>	8.91E-09	4.12	4.85E-02	-1.76	4.27E-02
41	<i>RORA</i>	1.28E-08	3.98	2.93E-02	1.59	3.61E-03
42	<i>SERTAD4</i>	6.58E-11	14.86	9.13E-03	1.91	3.45E-03
43	<i>SLC22A20</i>	1.83E-07	4.94	3.61E-03	2.69	1.86E-04
44	<i>SLC24A3</i>	5.49E-04	2.57	1.46E-02	1.88	2.28E-03
45	<i>SLC2A12</i>	1.66E-10	18.89	1.90E-02	2.55	1.40E-02
46	<i>SLC39A10</i>	8.63E-12	7.20	3.14E-02	1.73	4.61E-03
47	<i>SLC43A1</i>	1.37E-03	1.67	2.76E-03	-1.74	2.20E-02
48	<i>SLC45A4</i>	3.06E-11	4.30	4.69E-03	1.77	1.16E-04
49	<i>SLC6A20</i>	8.93E-03	2.63	3.45E-03	2.86	1.65E-03

50	<i>STAG3L3</i>	3.64E-12	6.44	1.31E-03	1.66	1.93E-04
51	<i>TCTE3</i>	2.84E-12	109.73	2.93E-02	1.52	1.14E-03
52	<i>TMCC2</i>	4.11E-11	9.92	3.02E-03	1.98	3.95E-04
53	<i>TRPS1</i>	1.23E-04	2.59	4.12E-02	1.56	2.11E-02
54	<i>TYW5</i>	2.84E-12	11.58	1.66E-03	2.65	4.39E-03
55	<i>UBE2W</i>	3.42E-12	9.91	1.30E-02	1.50	3.33E-03
56	<i>WDSUB1</i>	2.84E-12	20.06	3.77E-03	1.56	2.46E-03
57	<i>WDYHVI</i>	2.84E-12	15.31	5.80E-03	1.55	1.73E-02
58	<i>ZHX2</i>	1.32E-11	4.29	2.45E-02	1.63	9.63E-03
59	<i>ZNF469</i>	2.56E-11	11.30	1.97E-02	2.57	9.20E-05

Event, recurrence or metastasis; non-event, non-recurrence and non-metastasis; NT, non-tumor; T, tumor. ^{a)}p-values were calculated using the Wilcoxon test.